Skip to main content

Table 4 Postoperative recurrence events and post-recurrence treatment

From: Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer

 

Number of patients, n (%)

P

All(n = 373)

Pretreatment T790M

High(n = 151)

Low(n = 222)

Recurrence events

92

(24.7)

44

(29.1)

48

(21.6)

0.11

Locoregional

45

(12.1)

21

(13.9)

24

(10.8)

0.42

Distant

58

(15.5)

28

(18.5)

30

(13.5)

0.19

Post-recurrence treatment

  

 Local therapy

     

 Radiation therapy

24

 

13

 

11

 Surgery

4

 

1

 

3

 Systemic therapy

     

 Chemotherapy

9

 

5

 

4

 EGFR-TKI

53

 

25

 

28

 Best Supportive Care

5

 

1

 

4